

Claudius Mahr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1633657/publications.pdf>

Version: 2024-02-01

120
papers

2,210
citations

279487

23
h-index

253896

43
g-index

132
all docs

132
docs citations

132
times ranked

2201
citing authors

#	ARTICLE	IF	CITATIONS
1	A bridge-to-bridge approach to heart transplantation using extracorporeal membrane oxygenation and total artificial heart. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, 165, 1138-1148.e1.	0.4	5
2	Concomitant Respiratory Failure Can Impair Myocardial Oxygenation in Patients with Acute Cardiogenic Shock Supported by VA-ECMO. <i>Journal of Cardiovascular Translational Research</i> , 2022, 15, 217-226.	1.1	15
3	Concordance of Treatment Effect: An Analysis of The Society of Thoracic Surgeons Internacs Database. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1172-1182.	0.7	29
4	Variability in Blood Pressure Assessment in Patients Supported with the HeartMate 3™. <i>ASAIO Journal</i> , 2022, 68, 374-383.	0.9	8
5	Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2022, 7, 17.	3.0	77
6	A Computational Hemodynamics Approach to Left Ventricular Assist Device (LVAD) Optimization Validated in a Large Patient Cohort. <i>ASAIO Journal</i> , 2022, 68, 932-939.	0.9	2
7	Echocardiographic imaging of temporary percutaneous mechanical circulatory support devices. <i>Journal of Echocardiography</i> , 2022, 20, 77-86.	0.4	3
8	Anticoagulation in the HeartMate 3 Left Ventricular Assist Device: Are We Finally Moving the Needle?. <i>ASAIO Journal</i> , 2022, 68, 323-324.	0.9	4
9	The History of Durable Left Ventricular Assist Devices and Comparison of Outcomes: HeartWare, HeartMate II, HeartMate 3, and the Future of Mechanical Circulatory Support. <i>Journal of Clinical Medicine</i> , 2022, 11, 2022.	1.0	5
10	Global best practices consensus: Long-term management of patients with hybrid centrifugal flow left ventricular assist device support. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 1120-1137.e2.	0.4	10
11	Criteria for Defining Stages of Cardiogenic Shock Severity. <i>Journal of the American College of Cardiology</i> , 2022, 80, 185-198.	1.2	74
12	In Vitro Investigation of the Effect of Left Ventricular Assist Device Speed and Pulsatility Mode on Intraventricular Hemodynamics. <i>Annals of Biomedical Engineering</i> , 2021, 49, 1318-1332.	1.3	5
13	Abstract P435: Medical and Neurosurgical Interventions in Left Ventricular Assist Device-Associated Intracranial Hemorrhage. <i>Stroke</i> , 2021, 52, .	1.0	0
14	Abstract P283: Palliative and End-Of-Life Care After Left Ventricular Assist Device-Associated Intracranial Hemorrhage. <i>Stroke</i> , 2021, 52, .	1.0	0
15	Outcomes after heart transplantation and total artificial heart implantation: A multicenter study. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 220-228.	0.3	16
16	Two-Year Follow Up of the LATERAL Clinical Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e006912.	1.6	9
17	Estimation of Stressed Blood Volume in Patients With Cardiogenic Shock From Acute Myocardial Infarction and Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 1141-1145.	0.7	12
18	Compatibility of Novel Cardiogenic Shock Phenotypes from the Cardiogenic Shock Working Group (CSWG) with the SCAI Staging System. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, S128.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Reply. JACC: Heart Failure, 2021, 9, 323-324.	1.9	0
20	Clinical Outcomes Associated With Acute Mechanical Circulatory Support Utilization in Heart Failure Related Cardiogenic Shock. Circulation: Heart Failure, 2021, 14, e007924.	1.6	48
21	Cost-effectiveness of left ventricular assist devices as destination therapy in the United Kingdom. ESC Heart Failure, 2021, 8, 3049-3057.	1.4	6
22	Left Ventricular Assist Devices in Patients With Active Malignancies. JACC: CardioOncology, 2021, 3, 305-315.	1.7	5
23	Phenotyping Cardiogenic Shock. Journal of the American Heart Association, 2021, 10, e020085.	1.6	74
24	A Power Tracking Algorithm for Early Detection of Centrifugal Flow Pump Thrombosis. ASAIO Journal, 2021, 67, 1018-1025.	0.9	12
25	Impact of Age on Outcomes in Patients With Cardiogenic Shock. Frontiers in Cardiovascular Medicine, 2021, 8, 688098.	1.1	14
26	Long-Term Neurocognitive Outcome in Patients With Continuous Flow Left Ventricular Assist Device. JACC: Heart Failure, 2021, 9, 839-851.	1.9	4
27	Medical and Surgical Management of Left Ventricular Assist Device-Associated Intracranial Hemorrhage. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 106053.	0.7	7
28	Right Ventricular Dysfunction Is Common and Identifies Patients at Risk of Dying in Cardiogenic Shock. Journal of Cardiac Failure, 2021, 27, 1061-1072.	0.7	34
29	Acute Anticoagulation After Ischemic Stroke in Patients With Left Ventricular Assist Devices. ASAIO Journal, 2021, 67, e74-e76.	0.9	0
30	A Palpable Pulse Should Not Dictate Blood Pressure Strategy in Patients with Continuous Flow Ventricular Assist Devices. ASAIO Journal, 2020, 66, e39-e39.	0.9	2
31	Responding to Ventricular Assist Device Recalls: An Ethical Guide for Mechanical Circulatory Support Programs. ASAIO Journal, 2020, 66, 363-366.	0.9	1
32	Left Ventricular Assist Device Inflow Cannula Insertion Depth Influences Thrombosis Risk. ASAIO Journal, 2020, 66, 766-773.	0.9	26
33	Comparison of Neurologic Event Rates Among HeartMate II, HeartMate 3, and HVAD. ASAIO Journal, 2020, 66, 620-624.	0.9	20
34	Transitions In Hemometabolic Related Cardiogenic Shock. Journal of Cardiac Failure, 2020, 26, S56.	0.7	0
35	Accuracy of Doppler blood pressure measurement in HeartMate 3 ventricular assist device patients. ESC Heart Failure, 2020, 7, 4241-4246.	1.4	7
36	Left Ventricular Assist Device Caregiver Experiences and Health Outcomes: A Systematic Review of Qualitative and Quantitative Studies. Journal of Cardiac Failure, 2020, 26, 713-726.	0.7	7

#	ARTICLE	IF	CITATIONS
37	TAH Portable Driver: It's Alarming, but is It Broken?. Journal of Heart and Lung Transplantation, 2020, 39, S411-S412.	0.3	0
38	Long-Term Neurocognitive Outcomes in LVAD Recipients. Journal of Heart and Lung Transplantation, 2020, 39, S96-S97.	0.3	0
39	Variability in Blood Pressure Assessment in Patients Supported with HeartMate 3. Journal of Heart and Lung Transplantation, 2020, 39, S156-S157.	0.3	1
40	Cost-Effectiveness of a Small Intrapericardial Centrifugal LVAD versus Medical Management in Destination Therapy Patients in the UK. Journal of Heart and Lung Transplantation, 2020, 39, S159.	0.3	0
41	Antithrombotics after Intracranial Hemorrhage in Patients with Left Ventricular Assist Devices. Journal of Heart and Lung Transplantation, 2020, 39, S149.	0.3	0
42	Derivation and Validation of Three Novel Phenotypes of Cardiogenic Shock. Journal of Heart and Lung Transplantation, 2020, 39, S55.	0.3	0
43	Acute Anticoagulation after Ischemic Stroke in Patients with Left Ventricular Assist Devices. Journal of Heart and Lung Transplantation, 2020, 39, S396.	0.3	0
44	Complete Hemodynamic Profiling With Pulmonary Artery Catheters in Cardiogenic Shock Is Associated With Lower In-Hospital Mortality. JACC: Heart Failure, 2020, 8, 903-913.	1.9	163
45	Clinical and Hemometabolic Status Impact Transitions in Acute on Chronic Heart Failure Shock: Insights from the CSWG Registry. Journal of Heart and Lung Transplantation, 2020, 39, S187.	0.3	0
46	Cost-Effectiveness of a Small Intrapericardial Centrifugal Left Ventricular Assist Device. ASAIO Journal, 2020, 66, 862-870.	0.9	15
47	Cost-Effectiveness of Thoracotomy Approach for the Implantation of a Centrifugal Left Ventricular Assist Device. ASAIO Journal, 2020, 66, 855-861.	0.9	18
48	Invasive Hemodynamic Assessment and Classification of In-Hospital Mortality Risk Among Patients With Cardiogenic Shock. Circulation: Heart Failure, 2020, 13, e007099.	1.6	151
49	New Approach to the Treatment of Patients in Intermac 1 or 2 Biventricular Failure and on ECMO with the Syncardia Temporary Total Artificial Heart. Journal of Heart and Lung Transplantation, 2020, 39, S24.	0.3	0
50	Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure, 2020, 8, 789-799.	1.9	39
51	Outcome differences in acute vs. acute on chronic heart failure and cardiogenic shock. ESC Heart Failure, 2020, 7, 1118-1124.	1.4	7
52	Variant Interpretation for Dilated Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, e002480.	1.6	70
53	Commentary: Transcending acceptable, moving toward optimal: Standardizing surgical configurations of ventricular assist device therapy. Journal of Thoracic and Cardiovascular Surgery, 2020, 162, 1566-1567.	0.4	0
54	COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know. Journal of Molecular and Cellular Cardiology, 2020, 144, 12-14.	0.9	7

#	ARTICLE	IF	CITATIONS
55	Quality of life and rehabilitation after total artificial heart. <i>Annals of Cardiothoracic Surgery</i> , 2020, 9, 128-130.	0.6	2
56	Pulmonary Artery Catheter Usage and Mortality in Cardiogenic Shock. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, S54-S55.	0.3	3
57	Cost-Effectiveness of Thoracotomy Approach for the Implantation of a Small Intrapericardial Centrifugal LVAD. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, S366.	0.3	0
58	Ventricular Assist Device Driveline Dressing-Change Protocols: A Need for Standardization. A Report from the SimVAD Investigators. <i>Journal of Cardiac Failure</i> , 2019, 25, 695-697.	0.7	7
59	TCT-812 Modified SCAI Classification for Cardiogenic Shock Is Associated With Increasing In-Hospital Mortality: A Report From the Cardiogenic Shock Working Group Registry. <i>Journal of the American College of Cardiology</i> , 2019, 74, B795.	1.2	1
60	The ethical conundrum: Conflicting advocacy positions in advanced heart failure therapy. <i>Clinical Transplantation</i> , 2019, 33, e13489.	0.8	1
61	Accuracy of Doppler blood pressure measurement in continuous-flow left ventricular assist device patients. <i>ESC Heart Failure</i> , 2019, 6, 793-798.	1.4	17
62	Impact of Stroke Onset Severity on 2-Year Survival in Destination Therapy Patients Supported by Centrifugal Flow versus Axial Flow Ventricular Assist Devices. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, S68.	0.3	0
63	Cost-Effectiveness of a Small Intrapericardial Centrifugal LVAD versus Medical Management and Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, S132.	0.3	0
64	The Effect of Right Ventricular Arterial Uncoupling on Mortality in Cardiogenic Shock. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, S228.	0.3	0
65	Evaluation of a lateral thoracotomy implant approach for a centrifugal-flow left ventricular assist device: The LATERAL clinical trial. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 344-351.	0.3	145
66	Trials and Tribulations: Neurologic Events on Centrifugal Ventricular Assist Device Support. <i>ASAIO Journal</i> , 2019, 65, e81-e81.	0.9	0
67	Stroke in Ventricular Assist Device Patients: Reducing Complications and Improving Outcomes. <i>ASAIO Journal</i> , 2019, 65, 757-759.	0.9	4
68	Interpreting Neurologic Outcomes in a Changing Trial Design Landscape: An Analysis of HeartWare Left Ventricular Assist Device Using a Hybrid Intention to Treat Population. <i>ASAIO Journal</i> , 2019, 65, 293-296.	0.9	7
69	Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study. <i>Circulation</i> , 2019, 139, 155-168.	1.6	113
70	Blood damage in Left Ventricular Assist Devices: Pump thrombosis or system thrombosis?. <i>International Journal of Artificial Organs</i> , 2019, 42, 113-124.	0.7	28
71	Evaluating ventricular assist device outcomes internationally with a focus on neurological events. <i>Heart</i> , 2019, 105, 266-267.	1.2	4
72	Small Left Ventricular Size Is an Independent Risk Factor for Ventricular Assist Device Thrombosis. <i>ASAIO Journal</i> , 2019, 65, 152-159.	0.9	32

#	ARTICLE	IF	CITATIONS
73	Abstract TP107: Acute Anticoagulation After Stroke in Patients With Left Ventricular Assist Devices. Stroke, 2019, 50, .	1.0	0
74	Abstract 246: Applying a Quantitative, Cell Surface Glycoproteomic Approach to Understanding the Role of Human Cardiac Fibroblasts in Advanced Heart Failure. Circulation Research, 2019, 125, .	2.0	0
75	Left Ventricular Assist Device Inflow Cannula Angle and Thrombosis Risk. Circulation: Heart Failure, 2018, 11, e004325.	1.6	66
76	Blood Pressure Management Ameliorates the Severity of Neurological Events. Journal of Heart and Lung Transplantation, 2018, 37, S11.	0.3	2
77	Adverse Effects of Delayed Transplant Listing Among Patients With Implantable Left Ventricular Assist Devices. Journal of Cardiac Failure, 2018, 24, 243-248.	0.7	2
78	Five-year results of patients supported by HeartMate II: outcomes and adverse events. European Journal of Cardio-thoracic Surgery, 2018, 53, 422-427.	0.6	21
79	Biventricular Support With Intracorporeal, Continuous Flow, Centrifugal Ventricular Assist Devices. Annals of Thoracic Surgery, 2018, 105, 548-555.	0.7	32
80	Identification of Hypotensive Emergency Department Patients with Cardiogenic Etiologies. Shock, 2018, 49, 131-136.	1.0	7
81	21 PTT and Anti-Xa Activity in Adult Mechanical Circulatory Support Patients at a Large Academic Medical Center. American Journal of Clinical Pathology, 2018, 149, S174-S175.	0.4	1
82	Does Increasing Experience in Implementing the Blood Pressure Management Protocol in the ENDURANCE Supplemental Trial Result in Better Outcomes?. Journal of Heart and Lung Transplantation, 2018, 37, S283.	0.3	0
83	Change in Heart Rate from Pre-Implant to Discharge in Destination Therapy is Associated with Mortality and Admissions in LVAD Patients- A Substudy of the ENDURANCE trial. Journal of Heart and Lung Transplantation, 2018, 37, S278.	0.3	0
84	Impact of the Thoracotomy Implant Approach on Patient Self-Reported Quality of Life in the HVAD LATERAL Trial. Journal of Heart and Lung Transplantation, 2018, 37, S476.	0.3	0
85	HVAD: The ENDURANCE Supplemental Trial. JACC: Heart Failure, 2018, 6, 792-802.	1.9	185
86	The vortex of three-dimensional mapping with a centrifugal ventricular assist device. Europace, 2017, 19, euw155.	0.7	0
87	Outflow Graft Obstruction Treated With Transcatheter Management: A Novel Therapy for a New Diagnosis. Annals of Thoracic Surgery, 2017, 103, e101-e104.	0.7	20
88	Agreement between risk and priority for heart transplant: Effects of the geographic allocation rule and status assignment. Journal of Heart and Lung Transplantation, 2017, 36, 666-672.	0.3	7
89	The Treatment of Patients with Advanced Heart Failure Ineligible for Cardiac Transplantation with the HeartWare Ventricular Assist Device: Results of the ENDURANCE Supplement Trial. Journal of Heart and Lung Transplantation, 2017, 36, S10.	0.3	10
90	LVAD Outflow Graft Angle and Thrombosis Risk. ASAIO Journal, 2017, 63, 14-23.	0.9	67

#	ARTICLE	IF	CITATIONS
91	Where Do Patients with VADs Prefer to Spens Their Last Days?. Journal of Heart and Lung Transplantation, 2017, 36, S436.	0.3	0
92	Pulmonary function tests do not predict mortality in patients undergoing continuous-flow left ventricular assist device implantation. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 1959-1970.e1.	0.4	8
93	Intermittent Aortic Valve Opening and Risk of Thrombosis in Ventricular Assist Device Patients. ASAIO Journal, 2017, 63, 425-432.	0.9	30
94	The Benefit of Donor-Recipient Matching for Patients Undergoing Heart Transplantation. Journal of the American College of Cardiology, 2017, 69, 1707-1714.	1.2	15
95	Impact of LVAD Implantation Site on Ventricular Blood Stagnation. ASAIO Journal, 2017, 63, 392-400.	0.9	28
96	Ex-Vivo Perfusion of a Human Heart Recovered from a DCD Donor for 13 Hours on Organ Care System Platform. Journal of Heart and Lung Transplantation, 2017, 36, S45.	0.3	1
97	Effect of Transplant Rates on Benefit of Left Ventricular Assist Device versus Inotrope Support. Journal of Heart and Lung Transplantation, 2017, 36, S141-S142.	0.3	0
98	Durable mechanical circulatory support in teenagers and adults with congenital heart disease: A systematic review. International Journal of Cardiology, 2017, 245, 135-140.	0.8	25
99	Toward Genetics-Driven Early Intervention in Dilated Cardiomyopathy. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	41
100	Cell-Specific Pathways Supporting Persistent Fibrosis in Heart Failure. Journal of the American College of Cardiology, 2017, 70, 344-354.	1.2	37
101	Victims of Our Own Success and Failure. ASAIO Journal, 2016, 62, 1-2.	0.9	1
102	Reduction in Post-Heart Transplant ICU and Total Length of Stay by Standardization of Care Via a Multidisciplinary Approach. Journal of Heart and Lung Transplantation, 2016, 35, S205.	0.3	0
103	Comparison of Device-Related Infections between Two Continuous Flow Ventricular Assist Devices. Journal of Heart and Lung Transplantation, 2016, 35, S257.	0.3	0
104	Utility of Heart Transplant by Waitlist Mortality and Donor/Recipient Match. Journal of Heart and Lung Transplantation, 2016, 35, S85-S86.	0.3	0
105	Periportal fibrosis without cirrhosis does not affect outcomes after continuous flow ventricular assist device implantation. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 230-235.	0.4	5
106	Does Right Ventricular-Arterial Coupling Predict Early Right Heart Failure in LVAD Recipients?. Journal of Heart and Lung Transplantation, 2016, 35, S394-S395.	0.3	0
107	Systematic donor selection review process improves cardiac transplant volumes and outcomes. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 238-243.	0.4	32
108	Hold or fold Proteins in advanced heart failure and myocardial recovery. Proteomics - Clinical Applications, 2015, 9, 121-133.	0.8	2

#	ARTICLE	IF	CITATIONS
109	Late Surgical Bleeding Following Total Artificial Heart Implantation. Journal of Cardiac Surgery, 2015, 30, 771-774.	0.3	5
110	The Wisconsin Pharmacy Quality Collaborative - A Statewide Network of Community Pharmacists to Improve Heart Failure Outcomes. Journal of Cardiac Failure, 2015, 21, S133.	0.7	0
111	The Value of Elective Status 1A Time and the Effects of Delayed Transplant Listing Among Registrants With Mechanical Circulatory Support. Journal of Heart and Lung Transplantation, 2015, 34, S276.	0.3	1
112	Outcomes of External Repair of HeartMate II Percutaneous Leads. Journal of Heart and Lung Transplantation, 2015, 34, S27.	0.3	2
113	What Can You Do With an LVAD? Survey of Programs Implanting Durable Devices. Journal of Heart and Lung Transplantation, 2015, 34, S165.	0.3	0
114	Update on Post-Approval INTERMACs Registry of the HVAD System in Commercial Use. Journal of Heart and Lung Transplantation, 2015, 34, S195-S196.	0.3	1
115	First Report of the PAS INTERMACs Registry of the HVAD in Commercial Use. Journal of Heart and Lung Transplantation, 2014, 33, S36-S37.	0.3	0
116	Intermittent left ventricular assist device inflow tract obstruction by prolapsing papillary muscle detected by multi-detector computed tomography (MDCT). International Journal of Cardiology, 2014, 176, e13-e14.	0.8	6
117	Mechanical Support as Failure Intervention in Patients with Cavopulmonary Shunts (MFICS): Rationale and Aims of a New Registry of Mechanical Circulatory Support in Single Ventricle Patients. Congenital Heart Disease, 2013, 8, 182-186.	0.0	46
118	Value of Preoperative Upper Endoscopy in Patients Undergoing Laparoscopic Gastric Bypass. Obesity Surgery, 2006, 16, 142-146.	1.1	114
119	An unexpected cause of angina detected by ECG-gated cardiac computed tomography. International Journal of Cardiovascular Imaging, 2006, 22, 287-293.	0.7	0
120	Risk factors for pancreatic adenocarcinoma: Are we ready for screening and surveillance?. Current Gastroenterology Reports, 2005, 7, 122-127.	1.1	10